ClinicalTrials.gg
CompletedNCT05405660Updated Nov 6, 2025

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

A Phase 2 interventional study of barzolvolimab and Matching Placebo in Chronic Inducible Urticaria, sponsored by Celldex Therapeutics. Completed at 76 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-06.

Sponsored by Celldex Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 5 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jun 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Inducible Urticaria who remain symptomatic despite the use of H1-antihistamines.

Read the detailed description

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab in patients with Chronic Inducible Urticaria (Cold Urticaria [ColdU] or Symptomatic Dermographism [SD]) who remain symptomatic despite the use of H1-antihistamines.

There is a screening period of up to 4 weeks, followed by a 20-week treatment period where patients will receive either barzolvolimab 150mg, 300mg or placebo, and then a 24-week follow up period where all patients are observed.

02

Conditions studied

  • Chronic Inducible Urticaria

Keywords

  • CDX-0159
  • barzolvolimab
03

In context

Lead sponsor

Celldex Therapeutics is the lead sponsor of 45 studies on the registry; 3 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  1. Males and females, >/= 18 years of age.
  2. Diagnosis of chronic ColdU or SD >/= 3 months.
  3. Diagnosis of ColdU or SD despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:

    1. Recurrent pruritic wheals with or without angioedema due to ColdU or SD for >/= 6 weeks at any time prior to Visit 1 despite the use of H1-antihistamines.
    2. Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment and agree to stay on through trial.
    3. UCT \< 12 during the 14 days prior to treatment.
  4. Positive provocation test

    1. for ColdU patients: developing a wheal at the test site within 10 min after using TempTest® at any temperature at both screening (Visit 1) and randomization (Visit 3)
    2. for SD patients: developing a wheal at the test site within 10 min after using FricTest® with ≥ 3 pins at both screening (Visit 1) and randomization (Visit 3)
  5. Both males and females of must agree to use highly effective during the study and for 150 days after treatment.
  6. Willing and able to complete a daily symptom electronic diary and comply with study visits.

Key exclusion criteria:

  1. Women who are pregnant or nursing.
  2. Active Chronic spontaneous urticaria or other forms of CIndU besides ColdU or SD that may interfere with study assessments.
  3. Active, pruritic skin condition in addition to CIndU.
  4. Medical condition that would cause additional risk or interfere with study procedures.
  5. Known active , or infection.
  6. Vaccination of a within 2 months prior to study treatment (subjects must agree to avoid vaccination during the study). Inactivated vaccines are allowed such as seasonal influenza injection or COVID-19 vaccine.
  7. History of anaphylaxis

There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    barzolvolimab 150 mg in patients with Symptomatic Dermographism

    barzolvolimab 150 mg injection subcutaneous every 4 weeks for 20 weeks

    Biological: barzolvolimab

  • Experimental
    barzolvolimab 300 mg in patients with Symptomatic Dermographism

    barzolvolimab 300 mg injection subcutaneous every 8 weeks for 20 weeks

    Biological: barzolvolimab

  • Placebo comparator
    Placebo Comparator in patients with Symptomatic Dermographism

    Placebo injection subcutaneous every 4 weeks for 20 weeks

    Drug: Matching Placebo

  • Experimental
    barzolvolimab 150 mg in patients with Chronic Inducible Cold Urticaria

    barzolvolimab 150 mg injection subcutaneous every 4 weeks for 20 weeks

    Biological: barzolvolimab

  • Experimental
    barzolvolimab 300 mg in patients with Chronic Inducible Cold Urticaria

    barzolvolimab 300 mg injection subcutaneous every 8 weeks for 20 weeks

    Biological: barzolvolimab

  • Placebo comparator
    Placebo Comparator in patients with Chronic Inducible Cold Urticaria

    Placebo injection subcutaneous every 4 weeks for 20 weeks

    Drug: Matching Placebo

Interventions

  • Biologicalbarzolvolimab

    Subcutaneous Administration

    Also known as: CDX-0159

  • DrugMatching Placebo

    Subcutaneous Administration

06

What researchers measure

Primary outcomes

  1. Percentage of patients with a negative provocation test at week 12

    Percentage of patients with a negative provocation test for Cold Inducible Urticaria \[ColdU\] or Symptomatic Dermographism \[SD\]) at week 12 * For ColdU patients, a negative provocation test is defined as absence of wheals at the provocation site within 10 min at ≤ 4°C after provocation using TempTest® * For SD patients, a negative provocation test is defined as absence of wheals at the provocation site within 10 min at 0 pins after provocation using the FricTest®

    Time frame: From baseline to week 12

Secondary outcomes

  1. Change in provocation threshold and itch for ColdU

    Mean change from baseline to week 12 in critical temperature threshold (CTT) in patients with ColdU CTT is defined as threshold temperature at which wheals are triggered (highest temperature for cold), assessed at the 10-minute mark

    Time frame: From baseline to week 12

  2. Change in provocation threshold for SD

    Mean change from baseline to Week 12 in Critical Friction Threshold (CFT) in patients with SD CFT is the threshold pin number at which wheals are triggered, assessed at the 10-minute mark

    Time frame: From baseline to week 12

  3. Change in worst itch reported after provocation for ColdU

    Mean change in worst itch reported by numerical rating scale after provocation testing from baseline to week 12 in patients with ColdU

    Time frame: From baseline to week 12

  4. Combined patients with a negative provocation test at week 12

    Percentage of combined patients with a negative TempTest (ColdU) or FricTest (SD) at week 12

    Time frame: From baseline to week 12

  5. Change in worst itch reported after provocation for SD

    Mean change in worst itch reported by numerical rating scale after provocation testing from baseline to week 12 in patients with SD

    Time frame: From baseline to week 12

  6. Change in worst itch reported after provocation in both SD and ColdU

    Mean change in worst itch reported by numerical rating scale after provocation testing from baseline to week 12 in patients with SD and ColdU combined

    Time frame: From baseline to week 12

  7. Percentage of patients experiencing adverse events

    Percentage of patients experiencing treatment-emergent adverse events (TEAE) examined by ColdU patients, SD patients and in combination. A TEAE is any untoward medical occurrence in a patient administered a study treatment.

    Time frame: From baseline to week 20

07

Study locations

76 sites
  • Clinical Research Center of Alabama
    Birmingham, Alabama 35249, United States
  • Allervie Clinical Research
    Montgomery, Alabama 36106, United States
  • One of a Kind Clinical Research Center, LLC
    Paradise Valley, Arizona 85253, United States
  • Little Rock Allergy & Asthma CRC
    Little Rock, Arkansas 72205, United States
  • Kern Research, Inc
    Bakersfield, California 93301, United States
  • Allergy & Asthma Consultants
    Redwood City, California 94063, United States
  • IMMUNOe Research Centers
    Centennial, Colorado 80112, United States
  • Sarasota Clinical Research
    Sarasota, Florida 34239, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • Dawes Fretzin Dermatology Group, LLC
    Indianapolis, Indiana 46250, United States
  • Allergy & Asthma Specialists, PSC
    Owensboro, Kentucky 42301, United States
  • Institute for Asthma and Allergy, PC/Department of Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Respiratory Medicine Research Institute of Michigan, PLC
    Ypsilanti, Michigan 48197, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Allergy Partners of Kerrville
    Kerrville, Texas 78028, United States
  • Allergy Associates of Utah
    Murray, Utah 84107, United States
  • Outpatient Clinic for Individual Practice for Specialized Outpatient
    Razgrad, 7200, Bulgaria
  • Medical Center Iskar- EOOD Office of Clinical Allergology
    Sofia, 1504, Bulgaria
  • "Medical Center Ekselsior" OOD
    Sofia, Bulgaria
  • "University Multiprofile Hospital for Active Treatment 'Aleksandrovska" EAD, Clinic of Clinical Allergology
    Sofia, Bulgaria
  • Medical Center "SYNEXUS SOFIA", EOOD
    Sofia, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Prof. Dr. Stoyan Kirkovich" AD
    Stara Zagora, Bulgaria
  • Vahlberg & Pild Clinic
    Tallinn, 10134, Estonia
  • East Tallin Central Hospital
    Tallinn, 11312, Estonia
  • High Technology Hospital Medcenter
    Batumi, 6000, Georgia
  • Healthy Future
    Tbilisi, 0119, Georgia
  • Center of Allergy and Immunology
    Tbilisi, 0159, Georgia
  • Multiprofile Clinic Consilium Medulla
    Tbilisi, 0186, Georgia
  • Universitätsklinikum Augsburg
    Augsburg, Bavaria 86179, Germany
  • LMU Klinikum - Klinik und Poliklinik für Dermatologie und Allergologie DASZ-Dermato-Allergologisches Studien Zentrum
    München, Bavaria 80337, Germany
  • Universitaetsklinikum Giessen u. Marburg GmbH
    Marburg, Hesse 35043, Germany
  • Elbe Klinikum Buxtehude
    Buxtehude, Lower Saxony 21614, Germany
  • Hannover Medical University
    Hanover, Lower Saxony 30625, Germany
  • Klinikum Oldenburg gGmbH - Klinik f. Dermatologie u. Allergologie
    Oldenburg, Lower Saxony 26133, Germany
  • Universitätsklinikum Düsseldorf - Dermatologie
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • Universitätsklinikum Essen Klinikum f. Dermatologie, Venerologie u. Allergologie Hufelandstr
    Essen, North Rhine-Westphalia 45122, Germany
  • Universitätsklinikum Münster Klinik u. Poliklinik f. Dermatologie
    Münster, North Rhine-Westphalia 48149, Germany
  • Universitätsklinikum Dresden
    Dresden, Saxony 01307, Germany
  • Universitätsklinikum Schleswig-Holstein - Zentrum für entzündliche Hauterkrankungen
    Kiel, Schleswig-Holstein 24105, Germany
  • Institute of Allergology IFA
    Berlin, 12203, Germany
  • Universitätsklinikum Heidelberg - Dermatologie
    Heidelberg, 69120, Germany
  • Semmelweis Egyetem, ÁOK, Bőr-, Nemikórtani és Bőronkológiai Klinika
    Budapest, 1085, Hungary
  • Semmelweis Egyetem, ÁOK, Bőr-, Nemikórtani és Bőronkológiai Klinika
    Budapest, Hungary
  • Debreceni Egyetem Klinikai Központ (DEKK), Bőrgyógyászati Klinika
    Debrecen, H-4032, Hungary
  • Allergo-Derm Bakos Kft
    Szolnok, 5000, Hungary
  • Óbudai Egészségügyi Centrum
    Zalaegerszeg, 8900, Hungary
  • Balvi and Gulbene Hospital Union
    Balvi, LV-4501, Latvia
  • Pauls Stradins Clinical University Hospital
    Riga, LV-1002, Latvia
  • "LOR" Clinic
    Riga, LV-1004, Latvia
  • Children Clinical University Hospital
    Riga, LV-1004, Latvia
  • Consilium Medicum
    Riga, LV-1010, Latvia
  • JSC Ausros Medicinos Centras
    Kaunas, 49387, Lithuania
  • JSC Inlita
    Vilnius, 08406, Lithuania
  • Center of Allergy Diagnosis and Treatment
    Vilnius, LT-09109, Lithuania
  • Centrum Medyczne PLEJADY
    Krakow, 30-363, Poland
  • Malopolskie Centrum Alergologii
    Krakow, 31-624, Poland
  • Uniwersytecki Szpital Kliniczny nr 1 w Lodzi
    Lodz, 90-153, Poland
  • Luxderm Specjalistyczny Gabinet Dermatologiczny Prof. Doroty Krasowskiej
    Lublin, 20-573, Poland
  • Uniwersytecki Szpital Kliniczny w Opolu, Pododdział Chorób Wewnętrznych i Alergologii
    Opole, 45-401, Poland
  • Medicome Sp. z o.o.
    Oświęcim, 32600, Poland
  • Medicover Integrated Clinical Services Sp. zo.o.
    Torun, 87-100, Poland
  • Klinika Ambroziak sp. z o.o.
    Warsaw, 02-953, Poland
  • Iatros International
    Bloemfontein, Free State 9324, South Africa
  • WorthWhile Clinical Trials
    Benoni, Gauteng 1500, South Africa
  • Newtown Clinical Research
    Johannesburg, Gauteng 2113, South Africa
  • Ubuntu Clinical Research
    Lenasia, Gauteng 1827, South Africa
  • FCRN Clinical Trial Centre Vaal Triangle
    Vereeniging, Gauteng 1935, South Africa
  • Synapta Clinical Research
    Durban, KwaZulu-Natal 4001, South Africa
  • Dr PJ Sebastian
    Durban, KwaZulu-Natal 4092, South Africa
  • The University of Cape Town - Lung Institute
    Cape Town, Mowbray 7700, South Africa
  • HGU de Alicante
    Alicante, 03010, Spain
  • Hospital Bellvitge
    Barcelona, 8907, Spain
  • Hospital Vall d´ Hebron
    Barcelona, 9035, Spain
  • Universidad de Navarra
    Madrid, 28027, Spain
  • Hospital Regional Universitario de Málaga
    Málaga, 29009, Spain
  • Hospital Arnau de Vilanova
    Valencia, 46015, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jun 2024, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2022
First posted
Jun 6, 2022
StartActual
Jun 28, 2022
Primary completionActual
Jun 12, 2024
CompletionActual
Sep 12, 2025
Results delay requested
Jun 10, 2025
Last update
Nov 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05405660
Responsible party
Sponsor
First posted
Jun 6, 2022
Start date
Jun 28, 2022
Primary completion
Jun 12, 2024
Completion
Sep 12, 2025
Last update
Nov 6, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Barzolvolimab

Start the discussion